DAX24.217 +1,0%ESt505.379 +0,8%Top 10 Crypto15,90 -2,0%Dow44.633 -0,5%Nas21.098 -0,4%Bitcoin101.736 +0,1%Euro1,1549 ±0,0%Öl72,76 +3,4%Gold3.327 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Rheinmetall 703000 Heidelberger Druckmaschinen 731400 RENK RENK73 Lufthansa 823212 Volkswagen (VW) vz. 766403 Tesla A1CX3T PayPal A14R7U Deutsche Bank 514000 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 DroneShield A2DMAA Amazon 906866 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt deutlich im Plus -- Wall Street beendet Handel tiefer -- PayPal mit starkem Ergebnis -- D-Wave, Novo Nordisk, Uniper, UnitedHealth, HeidelDruck, TeamViewer, Hypoport, Tilray im Fokus
Top News
BioNTech-Aktie gibt nach: Partnerschaft mit Bristol Myers Squibb zur Fokussierung auf Krebsforschung BioNTech-Aktie gibt nach: Partnerschaft mit Bristol Myers Squibb zur Fokussierung auf Krebsforschung
Tilray-Aktie gibt kräftig nach: Tilray schockiert Anleger mit deutlich höherem Verlust Tilray-Aktie gibt kräftig nach: Tilray schockiert Anleger mit deutlich höherem Verlust
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Spyre Therapeutics Aktie

Handeln
14,50 EUR -0,10 EUR -0,68 %
STU
16,93 USD +0,13 USD +0,77 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone

Marktkap.886,82 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3D4LY

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00773J2024

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSYRE

Spyre Therapeutics Aktien News

DatumMeistgelesen
PR NewswireSpyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
PR NewswireSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on ...
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
ZacksWall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
PR NewswireSpyre Therapeutics to Participate in Upcoming June Investor Conferences
ZacksHow Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
PR NewswireSpyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics to Participate in Upcoming March Investor Conferences
PR NewswireSpyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
ZacksCan Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Added to the Nasdaq Biotechnology Index
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
PR NewswireSpyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PR NewswireSpyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disea...
PR NewswireSpyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment ...
PR NewswireSpyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics to Participate in Upcoming November Investor Conferences
PR NewswireSpyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combin...
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards
PR NewswireSpyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
PR NewswireSpyre Therapeutics to Participate in Upcoming Investor Conference
PR NewswireSpyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
PR NewswireSpyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics News

Spyre Therapeutics News: auf dieser Seite finden Sie alle Spyre Therapeutics News und Nachrichten zur Spyre Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Spyre Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Spyre Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.